Starling Oncology STLNW
NASDAQ STLNW
$0.04 -0.01 (-21.32%)
As of: Sep 9, 2026 · 12:49 PM EDT

Starling Oncology (STLNW) Preferred Stock Liabilities (2020 - 2021)

Starling Oncology's (STLNW) quarterly Preferred Stock Liabilities came in at $230.0 million in Q3 2021, up 13.03% on a YoY basis from $203.5 million in Q3 2020, and up 14.7% quarter-over-quarter from $200.5 million in Q2 2021.

Analysis

Starling Oncology (STLNW) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Starling Oncology (STLNW) has reported Preferred Stock Liabilities for 2 consecutive years, with $230.0 million the latest figure, recorded in Q3 2021.

  • For the quarter ending Q3 2021, Preferred Stock Liabilities rose 13.03% year-over-year to $230.0 million; the trailing twelve-month figure through Sep 2021 stood at $230.0 million (up 13.03% YoY), and the FY2020 full-year result was $230.0 million, changed N/A from the prior year.
  • Preferred Stock Liabilities climbed to $230.0 million in Q3 2021 per STLNW's latest filing, from $200.5 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $230.0 million in Q1 2020 and bottomed at $200.5 million in Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Davita 11.90 Bn 11.21 Bn 1.16 Bn -
2 RadNet 5.52 Bn 4.79 Bn 88.08 Mn -
3 Fresenius Medical Care AG 4.79 Bn 4.09 Bn 1.52 Bn -
4 Concentra Group Holdings Parent 4.28 Bn 4.12 Bn 192.10 Mn -
5 Privia Health 2.57 Bn 2.16 Bn - -
6 Pediatrix Medical 2.15 Bn 1.74 Bn - -
7 Progyny 2.12 Bn 1.89 Bn 89.30 Mn -
8 Surgery Partners 1.82 Bn 1.61 Bn 622.10 Mn -
9 U S Physical Therapy 1.17 Bn 1.14 Bn 41.94 Mn -
10 Starling Oncology 4.13 Mn -36.96 Mn 27.17 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 230.00 Mn
Jun 30, 2021 200.53 Mn
Mar 31, 2021 206.65 Mn
Dec 31, 2020 230.00 Mn
Sep 30, 2020 203.49 Mn
Jun 30, 2020 205.91 Mn
Mar 13, 2020 230.00 Mn